Abstract
P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are involved in intestinal barrier. Short-chain fatty acids (SCFAs) play important roles in maintaining intestinal barrier. In this study we explored how SCFAs affected the expression and function of intestinal P-gp and BCRP in rats. Rats received 150 mM acetate, propionate or butyrate in drinking water for 4 weeks. In SCFA-treated rats, the expression and function of intestinal P-gp were decreased, but those of intestinal BCRP were increased; intestinal p-p65 was also decreased, which was positively related to P-gp protein expression. Among the three SCFAs tested, butyrate exhibited the strongest induction or inhibitory effect, followed by propionate and acetate. Similar results were observed in mouse primary enterocytes and Caco-2 cells treated with acetate (5 mM), propionate (2 mM), or butyrate (1 mM). In Caco-2 cells, addition of butyrate, vorinostat, and valproate (two classic HDAC inhibitors), Bay117082 (selective inhibitor of NF-κB activation) or NF-κB p65 silencing significantly decreased the expression of P-gp and the level of phosphorylated p65 (p-p65). Furthermore, butyrate attenuated the expression of P-gp and p-p65 induced by TNF-α (NF-κB activator) and theophylline (HDAC activator). However, vorinostat, valproate, Bay117082, TNF-α or p65 silencing hardly affected BCRP protein expression. But GW9662 (selective PPARγ antagonist) or PPARγ silencing abolished BCRP induction by butyrate and troglitazone (PPARγ agonist). SCFAs-treated rats showed higher intestinal protein expression of PPARγ, which was positively related to BCRP protein expression. Butyrate increased plasma exposure of fexofenadine but decreased that of rosuvastatin following oral dose to rats. In conclusion, SCFAs exert opposite effects on the expression and function of intestinal P-gp and BCRP; butyrate downregulated P-gp expression and function possibly via inhibiting HDAC/NF-κB pathways; butyrate induced BCRP expression and function partly via PPARγ activation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Nakanishi T, Tamai I. Interaction of drug or food with drug transporters in intestine and liver. Curr Drug Metab. 2015;16:753–64.
Gutmann H, Hruz P, Zimmermann C, Straumann A, Terracciano L, Hammann F, et al. Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls. Digestion. 2008;78:154–62.
Sambuelli AM, Negreira SM, Gil AH, Huernos SP, Goncalves S, Toro MA, et al. Multidrug resistance gene (MDR-1) expression in the colonic mucosa of patients with refractory ulcerative colitis. Acta Gastroenterol Latinoam. 2006;36:23–32.
Buchman AL, Paine MF, Wallin A, Ludington SS. A higher dose requirement of tacrolimus in active Crohn’s disease may be related to a high intestinal P-glycoprotein content. Dig Dis Sci. 2005;50:2312–5.
Yu S, Yu Y, Liu L, Wang X, Lu S, Liang Y, et al. Increased plasma exposures of five protoberberine alkaloids from Coptidis Rhizoma in streptozotocin-induced diabetic rats: is P-GP involved? Planta Med. 2010;76:876–81.
Wang Z, Yang H, Xu J, Zhao K, Chen Y, Liang L, et al. Prediction of atorvastatin pharmacokinetics in high-fat diet and low-dose streptozotocin-induced diabetic rats using a semiphysiologically based pharmacokinetic model involving both enzymes and transporters. Drug Metab Dispos. 2019;47:1066–79.
Liu H, Liu L, Li J, Mei D, Duan R, Hu N, et al. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance ddition of butyrate, vorinostprotein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus. Drug Metab Dispos. 2012;40:1104–12.
Crowe A. The role of P-glycoprotein and breast cancer resistance protein (BCRP) in bacterial attachment to human gastrointestinal cells. J Crohn’s Colitis. 2011;5:531–42.
Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell host Microbe. 2015;17:662–71.
Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139:1619–25.
Jung TH, Park JH, Jeon WM, Han KS. Butyrate modulates bacterial adherence on LS174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway. Nutr Res Pr. 2015;9:343–9.
Tomova A, Bukovsky I, Rembert E, Yonas W, Alwarith J, Barnard ND, et al. The effects of vegetarian and vegan diets on gut microbiota. Front Nutr. 2019;6:47.
Rahat-Rozenbloom S, Fernandes J, Gloor GB, Wolever TM. Evidence for greater production of colonic short-chain fatty acids in overweight than lean humans. Int J Obes (Lond). 2014;38:1525–31.
Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010;18:190–5.
Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TM, Comelli EM. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr Diabetes. 2014;4:e121.
de Groot PF, Belzer C, Aydin O, Levin E, Levels JH, Aalvink S, et al. Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study. PLoS One. 2017;12:e0188475.
Samuelsson U, Ludvigsson J. The concentrations of short-chain fatty acids and other microflora-associated characteristics in faeces from children with newly diagnosed type 1 diabetes and control children and their family members. Diabet Med. 2004;21:64–7.
Lassenius MI, Fogarty CL, Blaut M, Haimila K, Riittinen L, Paju A, et al. Intestinal alkaline phosphatase at the crossroad of intestinal health and disease - a putative role in type 1 diabetes. J Intern Med. 2017;281:586–600.
Xu F, Zhu L, Qian C, Zhou J, Geng D, Li P, et al. Impairment of intestinal monocarboxylate transporter 6 function and expression in diabetic rats induced by combination of high-fat diet and low dose of streptozocin: involvement of butyrate-peroxisome proliferator-activated receptor-gamma activation. Drug Metab Dispos. 2019;47:556–66.
Vinolo MA, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC, Curi R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem. 2011;22:849–55.
Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB, et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene. 2002;21:1945–54.
Urakami-Takebayashi Y, Kuroda Y, Murata T, Miyazaki M, Nagai J. Pioglitazone induces hypoxia-inducible factor 1 activation in human renal proximal tubular epithelial cell line HK-2. Biochem Biophys Res Commun. 2018;503:1682–8.
Lin Y, Bircsak KM, Gorczyca L, Wen X, Aleksunes LM. Regulation of the placental BCRP transporter by PPAR gamma. J Biochem Mol Toxicol. 2017;31:e21880.
Lucas S, Omata Y, Hofmann J, Bottcher M, Iljazovic A, Sarter K, et al. Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss. Nat Commun. 2018;9:55.
Mei D, Li J, Liu H, Liu L, Wang X, Guo H, et al. Induction of multidrug resistance-associated protein 2 in liver, intestine and kidney of streptozotocin-induced diabetic rats. Xenobiotica. 2012;42:709–18.
Moriguchi J, Kato R, Nakagawa M, Hirotani Y, Ijiri Y, Tanaka K. Effects of lipopolysaccharide on intestinal P-glycoprotein expression and activity. Eur J Pharm. 2007;565:220–4.
Di Claudio F, Muglia CI, Smaldini PL, Orsini Delgado ML, Trejo FM, Grigera JR, et al. Use of a collagen membrane to enhance the survival of primary intestinal epithelial cells. J Cell Physiol. 2017;232:2489–96.
Fukushima A, Aizaki Y, Sakuma K. Short-chain fatty acids induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells. J Nutr. 2009;139:20–5.
Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab. 2007;8:383–93.
Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation. 2012;126:455–67.
Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004;200:689–95.
Kadiyala CS, Zheng L, Du Y, Yohannes E, Kao HY, Miyagi M, et al. Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC). J Biol Chem. 2012;287:25869–80.
Li X, Mu P, Qiao H, Wen J, Deng Y. JNK-AKT-NF-kappaB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells. Biochem Pharmacol. 2018;156:120–34.
Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003;22:90–7.
Montalbano AM, Albano GD, Bonanno A, Riccobono L, Di Sano C, Ferraro M, et al. Autocrine acetylcholine, induced by IL-17A via NFkappaB and ERK1/2 pathway activation, promotes MUC5AC and IL-8 synthesis in bronchial epithelial cells. Mediat Inflamm. 2016;2016:9063842.
Ferrari D, Speciale A, Cristani M, Fratantonio D, Molonia MS, Ranaldi G, et al. Cyanidin-3-O-glucoside inhibits NF-kB signalling in intestinal epithelial cells exposed to TNF-alpha and exerts protective effects via Nrf2 pathway activation. Toxicol Lett. 2016;264:51–8.
Pathak SM, Kumar AR, Musmade P, Udupa N. A simple and rapid high performance liquid chromatographic method with fluorescence detection for the estimation of fexofenadine in rat plasma–application to preclinical pharmacokinetics. Talanta. 2008;76:338–46.
Kamath AV, Yao M, Zhang Y, Chong S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci. 2005;94:233–9.
Liu H, Wang J, He T, Becker S, Zhang G, Li D, et al. Butyrate: a double-edged sword for health? Adv Nutr. 2018;9:21–9.
Bolognini D, Tobin AB, Milligan G, Moss CE. The pharmacology and function of receptors for short-chain fatty acids. Mol Pharmacol. 2016;89:388–98.
Tazoe H, Otomo Y, Karaki S, Kato I, Fukami Y, Terasaki M, et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed Res. 2009;30:149–56.
D’Souza WN, Douangpanya J, Mu S, Jaeckel P, Zhang M, Maxwell JR, et al. Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses. PLoS ONE. 2017;12:e0180190.
Pizzonero M, Dupont S, Babel M, Beaumont S, Bienvenu N, Blanque R, et al. Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem. 2014;57:10044–57.
Li M, van Esch B, Henricks PAJ, Folkerts G, Garssen J. The anti-inflammatory effects of short chain fatty acids on lipopolysaccharide- or tumor necrosis factor alpha-stimulated endothelial cells via activation of GPR41/43 and inhibition of HDACs. Front Pharmacol. 2018;9:533.
Napetschnig J, Wu H. Molecular basis of NF-kappaB signaling. Annu Rev biophysics. 2013;42:443–68.
Lehmann A, Denkert C, Budczies J, Buckendahl A-C, Darb-Esfahani S, Noske A, et al. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer. 2009;9:395.
Leus NG, Zwinderman MR, Dekker FJ. Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-kappaB-mediated inflammation. Curr Opin Chem Biol. 2016;33:160–8.
Jin UH, Cheng Y, Park H, Davidson LA, Callaway ES, Chapkin RS, et al. Short chain fatty acids enhance aryl hydrocarbon (Ah) responsiveness in mouse colonocytes and caco-2 human colon cancer cells. Sci Rep. 2017;7:10163.
Soliman ML, Combs CK, Rosenberger TA. Modulation of inflammatory cytokines and mitogen-activated protein kinases by acetate in primary astrocytes. J Neuroimmune Pharmacol 2013;8:287–300.
Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem. 2008;19:587–93.
Liu T, Li J, Liu Y, Xiao N, Suo H, Xie K, et al. Short-chain fatty acids suppress lipopolysaccharide-induced production of nitric oxide and proinflammatory cytokines through inhibition of NF-kappaB pathway in RAW264.7 cells. Inflammation. 2012;35:1676–84.
Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology. 2000;118:724–34.
Zhao L, Bin S, He HL, Yang JM, Pu YC, Gao CH, et al. Sodium butyrate increases P-gp expression in lung cancer by upregulation of STAT3 and mRNA stabilization of ABCB1. Anticancer Drugs. 2018;29:227–33.
Pasvanis S, Tremblay S, Dumais N. High sodium butyrate levels induce MDR1 activation in colorectal cells: impact of 15-deoxy-delta(12,14)-prostaglandin J(2) on the resistance to saquinavir. Biochem Biophys Res Commun. 2012;418:609–15.
Yan JK, Gong ZZ, Zhang T, Cai W. Sodium butyrate attenuates soybean oil-based lipid emulsion-induced increase in intestinal permeability of lipopolysaccharide by modulation of P-glycoprotein in Caco-2 cells. Biochem Biophys Res Commun. 2017;482:791–5.
Encarnacao JC, Pires AS, Amaral RA, Goncalves TJ, Laranjo M, Casalta-Lopes JE, et al. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. J Nutr Biochem. 2018;56:183–92.
Cummins CL, Mangravite LM, Benet LZ. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharmacol Res. 2001;18:1102–9.
Frommel TO, Coon JS, Tsuruo T, Roninson IB. Variable effects of sodium butyrate on the expression and function of the MDR1 (P-glycoprotein) gene in colon carcinoma cell lines. Int J Cancer. 1993;55:297–302.
El-Khoury V, Breuzard G, Fourre N, Dufer J. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. Br J Cancer. 2007;97:562–73.
Balaguer TM, Gomez-Martinez A, Garcia-Morales P, Lacueva J, Calpena R, Reverte LR, et al. Dual regulation of P-glycoprotein expression by trichostatin A in cancer cell lines. BMC Mol Biol. 2012;13:25.
Kinoshita M, Suzuki Y, Saito Y. Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. Biochem Biophys Res Commun. 2002;293:827–31.
Alex S, Lange K, Amolo T, Grinstead JS, Haakonsson AK, Szalowska E, et al. Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor gamma. Mol Cell Biol. 2013;33:1303–16.
Wachtershauser A, Loitsch SM, Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun. 2000;272:380–5.
Nepelska M, de Wouters T, Jacouton E, Béguet-Crespel F, Lapaque N, Doré J, et al. Commensal gut bacteria modulate phosphorylation-dependent PPARγ transcriptional activity in human intestinal epithelial cells. Sci Rep. 2017;7:43199.
Szatmari I, Vámosi G, Brazda P, Balint BL, Benko S, Széles L, et al. Peroxisome proliferator-activated receptor γ-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem. 2006;281:23812–23.
Davies GF, Ross AR, Arnason TG, Juurlink BH, Harkness TA. Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Lett. 2010;288:236–50.
Ban JO, Kwak DH, Oh JH, Park EJ, Cho MC, Song HS, et al. Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact. 2010;188:75–85.
Ruan H, Pownall HJ, Lodish HF. Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. J Biol Chem. 2003;278:28181–92.
Liu X. ABC family transporters. Adv Exp Med Biol. 2019;1141:13–100.
Koguchi T, Nakajima H, Wada M, Yamamoto Y, Innami S, Maekawa A, et al. Dietary fiber suppresses elevations of uric acid and allantoin in serum and urine induced by dietary RNA and increases its excretion to feces in rats. J Nutr Sci Vitaminol (Tokyo). 2002;48:184–93.
Sun Y, Sun J, Zhang P, Zhong F, Cai J, Ma A. Association of dietary fiber intake with hyperuricemia in U.S. adults. Food Funct. 2019;10:4932–40.
Murakami T, Bodor E, Bodor N. Modulation of expression/function of intestinal P-glycoprotein under disease states. Expert Opin Drug Metab Toxicol. 2020;16:59–78.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (No. 81573490, 81872930, and 81673505); “Cyan Blue”, “Six Talent Peaks” and “333” Project of Jiangsu Province, and “Double First-Class” university project (No. CPU2018GY22).
Author information
Authors and Affiliations
Contributions
Research design: QSX and XDL. Conduction of the experiments: QSX, JXZ, ML, PHL, LZ, LJ, MMJ, and XNL. Data analysis: QSX, ZJW, and XDL. Writing or revision of the manuscript: QSX, XDL, LL, ZJW, and LJ.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Xie, Qs., Zhang, Jx., Liu, M. et al. Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine. Acta Pharmacol Sin 42, 470–481 (2021). https://doi.org/10.1038/s41401-020-0402-x
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41401-020-0402-x
Keyword
This article is cited by
-
Postbiotics: Modulation of the Gut Microbiota and Potential for Association with Nanotechnology
Probiotics and Antimicrobial Proteins (2025)
-
Changes in the fecal microbiota of breast cancer patients based on 16S rRNA gene sequencing: a systematic review and meta-analysis
Clinical and Translational Oncology (2024)
-
Short-chain fatty acids in diseases
Cell Communication and Signaling (2023)
-
Correlation analysis of breast fibroadenoma and the intestinal flora based on 16S rRNA sequencing*
Oncology and Translational Medicine (2021)
